Warning letter
Sichuan Deebio Pharmaceutical Co. Ltd.: warning letter of Feb 14, 2024
FDA warning letter 669808 · Center for Drug Evaluation and Research | CDER
Key facts
| Reference number | 669808 |
|---|---|
| Company | Sichuan Deebio Pharmaceutical Co. Ltd. |
| Subject | CGMP/Active Pharmaceutical Ingredient (API)/Adulterated |
| Issue date | Feb 14, 2024 |
| Posted date | Feb 20, 2024 |
| Issuing office | Center for Drug Evaluation and Research | CDER |
| Product type | Drugs |
| Inspection city | Guanghan |
| Inspection start date | Sep 4, 2023 |
| Letter on fda.gov | fda.gov |
At a glance
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: